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The novel oral anticoagulants (NOACs) have been approved
for stroke prevention in atrial fibrillation (AF) and are fully
reimbursed by the Dutch health insurance agencies: as of
December 2012 for dabigatran and rivaroxaban followed by
apixaban in June 2013. To ensure optimal efficacy and safety
in daily clinical practice, the Dutch Ministry of Health pub-
lished a document (‘de Leidraad’) which contains a series of
precautionary measures that should be addressed before initi-
ation of the prescription of this new class of drugs [1].
The most important requirement is the presence of a hos-
pital protocol that describes how NOAC-related bleeding
complications are dealt with and how anticoagulation with
these agents is managed peri-operatively. Moreover, ‘de
Leidraad’ discusses the organisation of logistic issues related
to the implementation of the NOACs in clinical practice, such
as switching from vitamin-K antagonists to a NOAC, moni-
toring of renal function, and the registration of complications.
In this issue, Folkeringa and colleagues describe the
implementation of ‘de Leidraad’ in the Medical Centre
Leeuwarden and present the data of their first experience
with NOACs [2]. To facilitate the cardiologist, the function
of a specialised anticoagulation nurse was instituted as a
key player in the initiation and follow-up of outpatient
NOAC therapy.
For the management of a patient with AF, the effects of
nurse-led care on guideline adherence seem promising when
compared with standard of care, and the results of the ongoing
RACE-4 study (NCT01740037) will increase the evidence on
this topic and its potential impact on clinical outcome [3].
Moreover, the authors describe other potential values of the
specialised nurse, for example in the central registration of
patients receiving a NOAC and in maintaining the chain of
care for anticoagulation therapy, a task that was formerly
performed by the Thrombosis Service. The authors nicely
demonstrate that about a quarter of patients contact the outpa-
tient clinic with a variety of questions. A nurse can perform a
triage, and substantially reduce the physicians’ time spent with
these questions.
While the title and introduction suggest that the report on
the Leeuwarden model will give insight into the implementa-
tion of ‘de Leidraad’ into daily clinical practice, the authors
mainly focus on describing their population, the initiation of
treatment and the first (limited) data during follow-up. It
would have been interesting to know more about how the
abovementioned requirements from ‘de Leidraad’ were incor-
porated in the ‘Leeuwarden Model’.
With regard to the management of bleeding, two issues
should be addressed. With regard to logistics, there should be a
24/7 coverage to contact a physician in case of NOAC-related
bleeding questions. Of note, this should be the case for bleeding
on vitamin-K antagonists as well, as stated in the Dutch
National Standard Chain of Care on Antithrombotics
(Landelijke Standaard Ketenzorg Antistolling). In fact, the
introduction of NOACs has resulted in renewed awareness of
aspects that were already part of the ‘chain of anticoagulation
care’. A second aspect concerns the availability of a hospital
protocol on bleeding complications that also incorporates
NOAC-related bleeding.
In the Leeuwarden registration, peri-operative advice com-
prises only a minority of the questions so far. It should be
emphasised, however, that multidisciplinary awareness of
NOACs is of the utmost importance. In addition to a key
player, a so-called ‘case manager’, the regional availability
of a (multidisciplinary) protocol, which also addresses peri-
operative issues, could improve overall care (e.g. www.necf.
nl). Of note, it is important to ensure that dentists and general
practitioners (GPs) are aware of this protocol.
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Evenmore important thanwith the start of any other drug, a
letter to the GP is a key element of patient care. As GPs will
not prescribe NOACs themselves, they are not as familiar with
these drugs as with other drugs. Although dose adjustments of
the NOAC can only be performed by the prescriber, it is
important to inform the GPwhen dose adjustment is indicated,
to make sure that the patient is referred on time if, for example,
renal function deteriorates.
Many randomised trials have demonstrated that NOACs
are a safe and efficacious alternative to vitamin-K antagonists
in patients with AF. Appreciation of the abovementioned
aspects could further enhance their efficacy and safety in daily
clinical practice.
It should be noted that during the various trials there was no
or minimal experience with these agents and clear protocols
on how to act in case of complications were mostly absent.
Nonetheless, all NOACs proved to be at least as safe as
warfarin. Furthermore, a post-hoc analysis studying the man-
agement and outcomes of patients with major bleeding com-
plications demonstrated that patients who received dabigatran
had a shorter stay at the intensive care unit, with a trend
towards lower mortality when compared with warfarin thera-
py [4].
Finally, the authors report that negative publicity has also
been a reason for patients not to use a NOAC. Statements
concerning the absence of an antidote contribute to this, as
well as reports on an allegedly marked risk of gastrointestinal
bleeding. When informing the patient, it should be realised
that the management of major bleeding does not differ be-
tween NOACs and, for example, acenocoumarol. For bleed-
ing complications with the latter, vitamin K can only be used
as an antidote in non-urgent situations, given its slow mode of
action. Reports on a markedly increased risk of gastrointesti-
nal bleeding should be interpreted in the context that many of
the patients studied in these analyses used NOACs for indica-
tions that are not endorsed in daily clinical practice [5].
As for patients with AF, the risk of gastrointestinal bleeding
is only slightly increased for dabigatran 150mg twice daily and
rivaroxaban, and should be put in perspective to the interesting
overall safety profile (lower intracranial haemorrhage). For the
other NOACs no increased risk of gastrointestinal bleeding is
observed [5]. In analogy to the use of other antithrombotic
agents, the guidelines with regard to the prescription of proton
pump inhibitors should be followed.
In conclusion, Folkeringa and colleagues should be
commended for the emphasis they put on the ‘chain of care’
and a nurse-coordinated outpatient anticoagulation clinic
could be an attractive option to facilitate the physician.
Before local implementation of a similar strategy, we refer to
the valuable aspects mentioned in ‘de Leidraad’ to ensure that
this promising new class of drugs will reach its full potential in
daily clinical practice as well.
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